<DOC>
	<DOCNO>NCT02075983</DOCNO>
	<brief_summary>Our research part global effort develop vaccine HIV . We aim develop non-invasive , needle-free 'transcutaneous ' vaccine . It water-based solution place surface skin upper arm , hair strip away . The active component vaccine - DNA contain gene derive virus - enter hair follicle hair strip . The DNA get cell , use HIV gene make copy virus protein . These protein stimulate body 's immune system , hope , make able protect HIV infection . The research ass safety approach , good stimulating immune system . We combine 'transcutaneous ' vaccine 'intramuscular ' version inject muscle thigh , compare combination : intramuscular plus 'intradermal ' ( injection skin ) ; intramuscular add 'electroporation ' - use pulse electricity increase uptake DNA vaccine . We invite healthy men woman take part research . Volunteers first assess ensure eligible participate . A total 30 enrol receive three vaccination course 12 week . We assess effect vaccination record symptom experience volunteer , analyse sample blood . The research take place St Mary 's Hospital campus Imperial College London , UK . The DNA component vaccine experimental substance , monitor closely wellbeing men woman participate research .</brief_summary>
	<brief_title>Immunogenicity Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular , Intradermal Transcutaneous Routes</brief_title>
	<detailed_description>CUTHIVAC 001 randomise Phase I study aim explore safety immunogenicity different mode delivery GTU® DNA plasmid vaccine ( GTU®-multiHIV B clade ) healthy volunteer . Within study Transcutaneous ( TC ) delivery intramuscular ( IM ) delivery electroporation compare conventional intradermal ( ID ) intramuscular ( IM ) rout . The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes MultiHIV antigen synthetic fusion protein consist full-length polypeptide Rev , Nef , Tat , p17 p24 contain 20 Th CTL epitopes protease , reverse transcriptase ( RT ) gp160 region HAN2 HIV-1 B clade . 30 healthy male female volunteer 18 45 year old low risk HIV infection recruit . Group 1 serve reference proportion T-cell response . Preclinical data use low dos suggest may also antibody ( Ab ) responses . Electroporation ( EP ) show significantly increase immunogenicity DNA . Vaccine provide seal vial 2.0mg/ml practical limitation volume administer via route . To deliver 4mg timepoint , participant individual give two IM injection 2.0mg GTU®-MultiHIV DNA IM ( one leg ) visit . The dose give 1.0ml sterile PBS inject upper thigh muscle . The maximum volume give ID 0.1ml per injection , therefore maximum dose administer ID 0.2ml . Individuals Group 2 receive 0.2ml TC , novel needle-free method vaccine delivery previously show favour CD8+ T-cell IgA Ab responses without compromise overall immunogenicity . The objective study ass safety immunogenicity response three immunisation DNA- GTU® MultiHIV B clade vaccine administer via ID , TC IM route , without electroporation variety combination regimen .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Men woman age 18 45 year day screen 2 . BMI 1928 3 . Available followup duration study ( ~6 month screen ) 4 . Willing able give write informed consent 5 . At low risk HIV willing remain duration study define : history inject drug use previous ten year gonorrhoea syphilis last six month high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month unprotected anal intercourse last six month , outside relationship regular partner know HIV negative unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner 6 . Willing undergo HIV test 7 . Willing undergo genital infection screen 8 . If heterosexually active female , use effective method contraception partner ( combined oral contraceptive pill ; injectable implanted contraceptive ; consistent record condom use ; physiological anatomical sterility self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination 9 . If heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination 10 . Agree abstain donate blood three month end participation trial , longer necessary 11 . Registered GP least past three month 12 . Satisfactory response receive GP randomisation 1 . Pregnant lactate 2 . Use topical treatment injection application site within last four week 3 . No UV tan session strong sun exposure within four week prior study willingness avoid study period . 4 . Excessive terminal hair growth investigational skin area ( assessed reference photograph available screen visit . 5 . Individuals skinfold measurement ( cutaneous subcutaneous tissue ) upper right leave thigh exceeds 40 mm . 6 . Clinically relevant abnormality history examination include history grandmal epilepsy , seizure disorder history prior seizure history syncope faint episode within 1 year study entry . severe eczema liver disease inadequate hepatic function skin condition may interfere trial assessment injection site haematological , metabolic , gastrointestinal cardiopulmonary disorder include abnormal ECG . uncontrolled infection ; toxic shock syndrome autoimmune disease , immunodeficiency use immunosuppressives precede 3 month 7 . Known hypersensitivity component vaccine formulation use trial , seafood allergy severe multiple allergy drug pharmaceutical agent 8 . History severe local general reaction vaccination define 1. local : extensive , indurated redness swell involve anterolateral thigh major circumference arm , resolve within 72 hour 2. general : fever &gt; = 39.5oC within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour 9 . Receipt live attenuate vaccine within 60 day vaccine within 14 day enrolment 10 . Receipt experimental vaccine contain HIV antigen time past 11 . Receipt blood product immunoglobin within 4 month screen 12 . Participation another trial medicinal product , complete less 30 day prior enrolment 13 . HIV 1 2 positive indeterminate screen 14 . Positive hepatitis B surface antigen , hepatitis C antibody serology indicate active syphilis require treatment 15 . Grade 1 routine laboratory parameter ( see study specific table Appendix 3 definition ) . Hyperbilirubinaemia consider exclusion criterion confirm conjugated bilirubinaemia 16 . Current use electronic stimulation device , cardiac demand pacemaker , automatic implantable cardiac defibrillator , nerve stimulators , deep brain stimulators . 17 . Presence surgical traumatic metal implant sit administration 18 . Presence intrauterine device . 19 . Unable read speak English fluency level adequate full comprehension procedure require participation consent . 20 . Unlikely comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunisation</keyword>
	<keyword>DNA</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Electroporation</keyword>
	<keyword>Transcutaneous</keyword>
	<keyword>GTU MultiHIV B Clade</keyword>
	<keyword>Antibody</keyword>
	<keyword>Intramuscular</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>